Möchten Sie immer auf dem neuesten Stand bleiben?

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Outpatient Oncology Infusion Market Report 2026" has been added to ResearchAndMarkets.com's offering. The outpatient oncology infusion market is...

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Oncology Ablation Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive statistics, market size...

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Oncologists Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive statistics, including global...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Supportive Care Products Market Report 2026" has been added to ResearchAndMarkets.com's offering. This report offers valuable insights into...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "AI in Oncology for Analytical Solutions Market Report 2026" has been added to ResearchAndMarkets.com's offering. The AI in oncology for...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of...

Radioligand Therapeutics Market in Cancer Treatment to Reach $4.8 Billion by 2030, Reports BCC Research

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA...